1. Home
  2. BIPC vs CRSP Comparison

BIPC vs CRSP Comparison

Compare BIPC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brookfield Infrastructure Corporation

BIPC

Brookfield Infrastructure Corporation

HOLD

Current Price

$40.41

Market Cap

4.6B

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$49.80

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIPC
CRSP
Founded
2019
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
4.9B
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
BIPC
CRSP
Price
$40.41
$49.80
Analyst Decision
Sell
Buy
Analyst Count
1
17
Target Price
$45.00
$70.29
AVG Volume (30 Days)
975.7K
1.7M
Earning Date
04-29-2026
05-11-2026
Dividend Yield
5.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$289,590,000.00
Revenue This Year
$7.85
$807.72
Revenue Next Year
$5.94
$172.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
9169.85
52 Week Low
$34.18
$40.76
52 Week High
$51.72
$78.48

Technical Indicators

Market Signals
Indicator
BIPC
CRSP
Relative Strength Index (RSI) 45.04 45.11
Support Level $39.00 $46.15
Resistance Level $41.08 $59.61
Average True Range (ATR) 1.11 2.91
MACD -0.13 -0.35
Stochastic Oscillator 0.40 9.92

Price Performance

Historical Comparison
BIPC
CRSP

About BIPC Brookfield Infrastructure Corporation

Brookfield Infrastructure Corp is an indirect subsidiary of the partnership of the diversified infrastructure owner and operators. Its business is comprised of a U.K. regulated distribution operation, a Brazilian regulated natural gas transmission operation and an international intermodal logistics operation. Geographically, the company generates a majority of its revenue from Brazil and rest from United Kingdom, United States, France, Switzerland, Singapore, China, Denmark, Hong Kong, Germany and Others.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: